Cargando…
Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome
Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in...
Autores principales: | Lunde, Sigrid, Kristoffersen, Einar K., Sapkota, Dipak, Risa, Kristin, Dahl, Olav, Bruland, Ove, Mella, Olav, Fluge, Øystein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990178/ https://www.ncbi.nlm.nih.gov/pubmed/27536947 http://dx.doi.org/10.1371/journal.pone.0161226 |
Ejemplares similares
-
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment
por: Fluge, Øystein, et al.
Publicado: (2015) -
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study
por: Fluge, Øystein, et al.
Publicado: (2011) -
Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients
por: Rekeland, Ingrid G., et al.
Publicado: (2022) -
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
por: Fluge, Øystein, et al.
Publicado: (2009) -
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study
por: Rekeland, Ingrid G., et al.
Publicado: (2020)